HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Remacha, A. F Articles by Fuster, M. Search for Related Content PubMed PubMed Citation Articles by Remacha, A. F Articles by Fuster, M. Agricola Articles by Remacha, A. F Articles by Fuster, M.

Vitamin B-12 metabolism in HIV-infected patients in the age of highly active antiretroviral therapy: role of homocysteine in assessing vitamin B-12 status^1,2,3

¹ From the Departments of Hematology (AFR and PS) and Internal Medicine (JC, MB, and MF), Hospital de Sant Pau, Barcelona, Spain.

Background: Before the advent of highly active antiretroviral therapy (HAART), 20% and 10% of HIV-infected patients had low vitamin B-12 and red blood cell folate (RBCF) concentrations, respectively. However, few patients had real vitamin B-12 deficiency.

Objective: We evaluated the prevalence of low vitamin B-12 and RBCF concentrations in HIV-infected patients receiving HAART and the usefulness of serum homocysteine (sHcy) for differentiating patients with deficiency from those with harmlessly low vitamin B-12.

Design: The prevalence of low vitamin B-12 and RBCF was evaluated in 126 HIV-infected patients receiving HAART. Moreover, sHcy concentrations were evaluated in 40 HIV-infected patients with low vitamin B-12 and in 37 HIV-infected patients with low RBCF and were compared with those in 128 HIV-infected patients with normal vitamin B-12 and RBCF. sHcy was used to monitor treatment with vitamin B-12 and folic acid in 28 patients (24 with low vitamin B-12 and RBCF and 4 with hyperhomocysteinemia but normal vitamin B-12 and RBCF).

Results: The prevalence of low vitamin B-12 was significantly lower in patients receiving HAART than in previously studied patients who did not receive HAART (8.7% compared with 27%). Nine of the 40 patients (22.5%) with low vitamin B-12 ( 200 pmol/L) had hyperhomocysteinemia (> 17.5 µmol homocysteine/L). Nineteen (51.4%) of the 37 patients with low RBCF ( 580 nmol/L, percentile 10) had hyperhomocysteinemia. Among the 9 patients with an RBCF concentration 450 nmol/L (percentile 2.5), all had hyperhomocysteinemia. The treatment with vitamin B-12 and folic acid normalized sHcy concentrations.

Conclusions: The prevalence of low vitamin B-12 decreased after the introduction of HAART. The study of sHcy is useful for detecting HIV-infected patients with low vitamin B-12 and real deficiency.

Key Words: HIV • vitamin B-12 • folate • homocysteine • highly active antiretroviral therapy • HAART

This article has been cited by other articles:

				P. K Drain, R. Kupka, F. Mugusi, and W. W Fawzi Micronutrients in HIV-positive persons receiving highly active antiretroviral therapy Am. J. Clinical Nutrition, February 1, 2007; 85(2): 333 - 345. [Abstract] [Full Text] [PDF]

				D. Fuchs, K. Schroecksnadel, and R. Zangerle Increase in vitamin B-12 during highly active antiretroviral therapy Am. J. Clinical Nutrition, November 1, 2003; 78(5): 1046 - 1046. [Full Text] [PDF]

				A. F Remacha and J. Cadafalch Reply to D Fuchs et al Am. J. Clinical Nutrition, November 1, 2003; 78(5): 1046 - 1047. [Full Text] [PDF]